Rezolute, Inc. (RZLT) stocks plummet 90% after Phase 3 sunRIZE trial failure for ersodetug, investigated by Hagens Berman.
In San Francisco on December 18, 2025, Rezolute, Inc. (NASDAQ: RZLT) experienced a significant drop in share price, plummeting by up to 90% on December 11, 2025. This decline followed the announcement of the failure of the Phase 3 sunRIZE trial for ersodetug ("erso"). The specific trial focused on erso, and the company faced challenges with its Phase 3 trial results.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments